Persister M. leprae after introductory rifampicin followed by dapsone therapy.
Lepromatous patients of "Introductory Rifampicin therapy' (Lepr. India, 50: 1978) who received 300 mg Rifampicin daily for 3 months followed by 50-100 mg DDS daily for another 21 months are investigated for persisters in the skin. Mouse foot pad results revealed that at the end of 2 years of treatment viable M. leprae are still persisting in 3 out of 6 patients.
D000818:Animals; D003622:Dapsone / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D006801:Humans; D007918:Leprosy / Q000188:drug therapy*; D051379:Mice; D012293:Rifampin / Q000627:therapeutic use*
D003622:Dapsone; D012293:Rifampin